CHUV
Les activités du CHUV
MENU
Service de gastro-entérologie
et d’hépatologie
Accueil > Recherche > Publications > 2014

Publications


Articles originaux et de revue


2014

1: Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M.
    Hepatitis C virus infection and kidney transplantation in 2014: what's new?
Am J Transplant, 2014;14:2206-20.
2: Bernasconi E, D'Angelo F, Michetti P, Velin D.
    Critical Role of the GM-CSF Signaling Pathway in Macrophage Pro-Repair Activities.
Pathobiology, 2014;81:183-9
3: Boettler T, Moradpour D, Thimme R, Zoulim F.
    Bridging Basic Science and Clinical Research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis.
J Hepatol, 2014;61:696-705
4: Boukadida C, Marnata C, Montserret R, Cohen L, Blumen B, Gouttenoire J, Moradpour D, Penin F, Martin A.
    NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies.
J Virol, 2014;88:7426-44
5: Burgmann K and Moradpour D.
    Hepatitis C - ein Update.
Der informierte Arzt, 2014;4:17-19.
6: Burgmann K., Fraga M., Schoepfer A.M., Yun P.
    Colites microscopiques--quoi de neuf ? [Microscopic colitis: update 2014].
Rev Med Suisse, 2014;10:1586-1590
7: Chtioui H, Buclin T and Moradpour D.
    Nouveaux traitements de l'hépatite C : aspects pharmacologiques et potential d'interaction.
Rev Med Suisse 2014;10:1612-1616.
8: Deltenre P and Moradpour D.
    Actualités diagnostiques et thérapeutiques dans le domaine de l'encéphalopathie hépatique.
Rev Med Suisse 2014;10:1600-1606.
9: Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski A, Truant S, Pruvot FR, Dharancy S.
    Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
Dig Liv Dis, 2014;46:157-63.
10: Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva-Delcambre V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdan Yazdanpanah.
    Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
J Hepatol, 2014;61:7-14.
11: Durand F, Buyse S, Francoz C, Laouénan C, Bruno O, Belghiti J, Moreau R, Vilgrain V, Valla D.
    Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography
J Hepatol. 2014 Jun;60(6):1151-7
12: Enderlin Vaz da Silva Z, Lehr HA, Velin D
    In vitro and in vivo repair activities of undifferentiated and classically and alternatively activated macrophages.
Pathobiology, 2014;81:86-93.
13: Frei P, Leucht A-K, Held U, Kofmehl R, Schmitt J, Mertens J, Rau M, Baur K, Gerlach TJ, Negro F, Heim MH, Moradpour D, Cerny A, Dufour J-F, Müllhaupt B, Geier A, and the Swiss Hepatitis C Cohort Study Group.
    Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-a and ribavirin in patients with chronic hepatitis C.
Liver Int, 2014;34:551-557.
14: Frei P., Misselwitz B., Prakash M.K., Schoepfer A.M., Prinz Vavricka B.M., Müllhaupt B., Fried M., Lehmann K., Ammann R.W., Vavricka S.R.
    Late biliary complications in human alveolar echinococcosis are associated with high mortality.
World J Gastroenterol, 2014;20:5881-8.
15: Frossard J-L and Moradpour D.
    Café et pancréas : la demi-vie de la vérité en médecine [Editorial].
Rev Med Suisse, 2014;10:1579
16: Gouttenoire J, Montserret R, Paul D, Castillo R, Meister S, Bartenschlager R, Penin F, Moradpour D.
    Aminoterminal amphipathic a-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production.
PLoS Pathog, 2014;10:e1004501.
17: Hessler R, Godat S, Fraga M, Burgmann K, Doerig C, Deltenre P, Schoepfer A.
    [Highlights in gastroenterology and hepatology 2013].
Rev Med Suisse, 2014;10:41-4.
18: Hiroz P., Vavricka S.R., Fournier N., Safroneeva E., Pittet V., Rogler G., Schoepfer A.M., Swiss Inflammatory Bowel Diseases Cohort Study Group
    Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort
Scand J Gastroenterol, 2014;49:1207-18
19: Hoggart CJ, Venturini G, Mangino M, Gomez F, Ascari G, Zhao JH, Teumer A, Winkler TW, Tšernikova N, Luan J, Mihailov E, Ehret GB, Zhang W, Lamparter D, Esko T, Macé A, Rüeger S, Bochud PY, Barcella M, Dauvilliers Y, Benyamin B, Evans DM, Hayward C, Lopez MF, Franke L, Russo A, Heid IM, Salvi E, Vendantam S, Arking DE, Boerwinkle E, Chambers JC, Fiorito G, Grallert H, Guarrera S, Homuth G, Huffman JE, Porteous D; Generation Scotland Consortium; The LifeLines Cohort study; The GIANT Consortium, Moradpour D, Iranzo A, Hebebrand J, Kemp JP, Lammers GJ, Aubert V, Heim MH, Martin NG, Montgomery GW, Peraita-Adrados R, Santamaria J, Negro F, Schmidt CO, Scott RA, Spector TD, Strauch K, Völzke H, Wareham NJ, Yuan W, Bell JT, Chakravarti A, Kooner JS, Peters A, Matullo G, Wallaschofski H, Whitfield JB, Paccaud F, Vollenweider P, Bergmann S, Beckmann JS, Tafti M, Hastie ND, Cusi D, Bochud M, Frayling TM, Metspalu A, Jarvelin MR, Scherag A, Smith GD, Borecki IB, Rousson V, Hirschhorn JN, Rivolta C, Loos RJ, Kutalik Z.
    Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent-of-origin effect on body mass index.
PLoS Genet, 2014;10:e1004508.
20: Kuchen T., Straumann A., Safroneeva E., Romero Y., Bussmann C., Vavricka S., Netzer P., Reinhard A., Portmann S., Schoepfer A.M.
    Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.
Allergy, 2014;69:1248-54.
21: Lange CM, Bellecave P, Dao Thi VL, Tran HTL, Penin F, Moradpour D, Gouttenoire J.
    Determinants for membrane association of the hepatitis C virus NS2 protease domain.
J Virol, 2014;88:6519-6523
22: Lange CM, Gouttenoire J, Duong FHT, Morikawa K, Heim MH, Moradpour D
    Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to interferon-alpha
J Immunol, 2014;192:6037-6044.
23: Maître S, Maniu CM, Buss G, Maillard MH, Spertini F, Ribi C.
    [Food allergy or food intolerance?].
Rev Med Suisse, 2014;10:846-853
24: Maillard M, Bega H, Uhlig HH, Barnich N, Grandjean T, Chamaillard M, Michetti P, Velin D.
    Toll-interacting protein modulates colitis susceptibility in mice.
Inflamm Bowel Dis, 2014;20:660-70
25: Maillard M, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; The Swiss IBD Cohort Study Group.
    Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.
J Crohns Colitis, 2014;8:825-34.
26: Manser CN, Frei P, Grandinetti T, Biedermann L, Mwinyi J, Vavricka SR, Schoepfer A, Fried M, Rogler G; the Investigators of the Swiss IBD Cohort Study.
    Risk Factors for Repetitive Ileocolic Resection in Patients with Crohn's Disease: Results of an Observational Cohort Study.
Inflamm Bowel Dis, 2014;20:1548-54.
27: Masin M, Vazquez J, Rossi S, Groeneveld SJ, Samson N, Schwalie PC, Deplancke B, Frawley LE, Gouttenoire J, Moradpour D, Oliver TG, Meylan E.
    GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.
Cancer Metab, 2014;2:11.
28: Moawad FJ, Schoepfer AM, Safroneeva E, Ally MR, Chen YJ, Maydonovitch CL, Wong RK.
    Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings.
Aliment Pharmacol Ther, 2014;39:603-8
29: Moawad FJ, Schoepfer AM.
    Commentary: the proton pump inhibitor test - does it have a role in eosinophilic oesophagitis? Authors' reply.
Aliment Pharmacol Ther, 2014;39:897-8
30: Morard I, Clément S, Calmy A, Mangia A, Cerny A, Dufour J-F, Gorgievski M, Heim MH, Malinverni R, Moradpour D, Müllhaupt B, Semela D, Pascarella S, Bochud P-Y, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group.
    Clinical significance of the CCR5^32 allele in hepatitis C
PLoS One, 2014;9:e106424.
31: Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HTL, Lange CM, Dill MT, Heim MH, Donzé O, Penin F, Quadroni M, Moradpour D.
    Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.
Hepatology, 2014;59:423-433.
32: Moyat M, Velin D.
    Immune responses to Helicobacter pylori infection.
World J Gastroenterol, 2014;20:5583-93
33: Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, Cardona V, Dubois A, duToit G, Eigenmann P, Fernandez Rivas M, Halken S, Hickstein L, Høst A, Knol E, Lack G, Marchisotto MJ, Niggemann B, Nwaru BI, Papadopoulos NG, Poulsen LK, Santos AF, Skypala I, Schoepfer A, Van Ree R, Venter C, Worm M, Vlieg-Boerstra B, Panesar S, de Silva D, Soares-Weiser K, Sheikh A, Ballmer-Weber BK, Nilsson C, de Jong NW, Akdis CA; EAACI Food Allergy and Anaphylaxis Guidelines Group.
    EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy.
Allergy, 2014;69:1008-25.
34: Pittet V, Rogler G, Mottet C, Froehlich F, Michetti P, de Saussure P, Burnand B, Vader JP; Swiss IBD Cohort Study Group.
    Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients.
Scand J Gastroenterol, 2014;49:662-73.
35: Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P.
    The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.
J Crohns Colitis, 2014;8:1427-37
36: Quarato G, Scrima R, Ripoli M, Agriesti F, Moradpour D, Capitanio N, Piccoli C.
    Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression.
Biochem Pharmacol, 2014;89:545-556.
37: Sauter B, Beglinger C, Girardin M, Macpherson A, Michetti P, Schoepfer A, Seibold F, Vavricka SR, Rogler G
    Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead 'Optimised Monitoring' Recommendations.
Digestion, 2014;89:299-309.
38: Schaffer T, Schoepfer AM, Seibold F; on behalf of the Swiss IBD Cohort Study Group.
    Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
J Crohns Colitis, 2014;8:1125-32
39: Schoepfer A, Safroneeva E.
    Activity assessment of eosinophilic esophagitis.
Dig Dis, 2014;32:98-101.
40: Schoepfer A.M., Bortolotti M., Pittet V., Mottet C., Gonvers J.J., Reich O., Fournier N., Vader J.P., Burnand B., Michetti P., Froehlich F.
    The gap between scientific evidence and clinical practice : 5-aminosalicylates are frequently used for the treatment of Crohn's disease
Aliment Pharmacol Ther, 2014;40:930-7.
41: Schoepfer A.M., Straumann A., Panczak R., Coslovsky M., Kuehni C.E., Maurer E., Haas N.A., Romero Y., Hirano I., Alexander J.A., Gonsalves N., Furuta G.T., Dellon E.S., Leung J., Collins M.H., Bussmann C., Netzer P., Gupta S.K., Aceves S.S., Chehade M., Moawad F.J., Enders F.T., Yost K.J., Taft T.H., Kern E., Zwahlen M., Safroneeva E., International Eosinophilic Esophagitis Activity Index Study Group
    Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.
Gastroenterology, 2014;147:1255-66.e21
42: Schoepfer A.
    Treatment of eosinophilic esophagitis by dilation.
Dig Dis, 2014;32:130-3.
43: Schoepfer AM, Hirano I, Katzka DA.
    Eosinophilic esophagitis: overview of clinical management.
Gastroenterol Clin North Am, 2014;43:329-44.
44: Straumann A, Schoepfer A.
    Update on basic and clinical aspects of eosinophilic oesophagitis.
Gut, 2014;63:1355-63
45: Terczyńska-Dyla E, Bibert S, Duong FHT, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Müllhaupt B, Negro F, Santoro R, Semela D, Semmo N, Heim MH, Bochud P-Y, Hartmann R.
    Reduced IFNl4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
Nat Commun 2014;5:5699.
46: Thimme R, Heim M, Baumert T, Nassal M, Moradpour D.
    Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie. (part 1)
Dtsch Med Wochenschr, 2014;139:655-659
47: Thimme R, Heim M, Baumert T, Nassal M, Moradpour D.
    Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie. (part 2)
Dtsch Med Wochenschr, 2014;139:778-782
48: Tissot F, Maillard MH.
    [Clostridium difficile infections: update on new European recommendations].
Rev Med Suisse, 2014;10:913-919
49: Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P.
    Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data.
Hepatology, 2014;59:2170-77.
50: Vavricka S.R., Radivojevic S., Manser C.N., Frei P., Burri E., Fried M., Schoepfer A., Peyrin-Biroulet L., Michetti P., Rogler G., Biedermann L.
    Addressing current treatment challenges in Crohn's disease in real life: A physician's survey.
Dig Liver Dis, 2014;46:1066-71
51: Vavricka SR, Rogler G, Maetzler S, Misselwitz B, Safroneeva E, Frei P, Manser CN, Biedermann L, Fried M, Higgins P, Wojtal KA, Schoepfer AM.
    High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients.
J Crohns Colitis, 2014;8:191-9.
52: Vavricka SR, Schoepfer AM, Scharl M, Rogler G.
    Steroid use in Crohn's disease.
Drugs, 2014;74:313-24.
53: Vietti Violi N, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; Swiss Inflammatory Bowel Disease Cohort Study Group.
    Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort.
AJR Am J Roentgenol, 2014;203:62-9.



1:
   
2:
   
3:
   
4:
   
5:
   
6:
   
7: